Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Once-a-Day Epilepsy Drug Is Effective for Partial Seizures

16.10.2007
The epilepsy drug lamotrigine is effective in controlling partial seizures when taken once a day as an added therapy, according to a study published in the October 16, 2007, issue of Neurology®, the medical journal of the American Academy of Neurology.

“These results are important because maintaining stable blood levels of epilepsy drugs and good control of seizures depends on people taking their medications reliably and consistently,” said study author Dean Naritoku, MD, of Southern Illinois University in Springfield and member of the American Academy of Neurology. “The more often people have to remember to take their medication each day, the more likely they are to miss a dose. Once-a-day dosing is more convenient for patients.”

The study involved 239 people from the United States and several other countries. Participants were age 13 and older with partial seizures not fully controlled by medication. Some of the participants also had secondary generalized seizures. The participants were already taking one to two epilepsy medications; lamotrigine was added to their therapy. They received either lamotrigine in an extended-release formula or placebo for 19 weeks.

Those taking lamotrigine as an added therapy had 46 percent fewer partial seizures during the study, compared to 24 percent fewer for those taking a placebo. In addition, 42 percent of those taking lamotrigine as an added therapy reduced their seizure frequently by at least half by the end of the study, compared to 24 percent of those taking a placebo.

“This new once daily medication may be an important option for people with epilepsy that could significantly increase their compliance with prescribed treatment,” said Naritoku.

The most common side effects were headache, which was experienced by 17 percent of those taking lamotrigine and 15 percent of those taking placebo, and dizziness, which was experienced by 18 percent of those taking lamotrigine and five percent of those taking placebo.

The study was sponsored and conducted by GlaxoSmithKline.

The American Academy of Neurology, an association of more than 20,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease, and multiple sclerosis.

For more information about the American Academy of Neurology, visit www.aan.com.

Angela Babb | AAN Press
Further information:
http://www.aan.com/press

More articles from Studies and Analyses:

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

nachricht Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Researchers devise microreactor to study formation of methane hydrate

23.08.2017 | Materials Sciences

ShAPEing the future of magnesium car parts

23.08.2017 | Automotive Engineering

New insights into the world of trypanosomes

23.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>